Immunotherapeutic Approaches to the Management of Head and Neck Cancer
Published: | Updated:
Experts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.
Xinyu Nan, MD
Advertisement
Articles by Xinyu Nan, MD
Advertisement
Latest Updated Articles
Immunotherapeutic Approaches to the Management of Head and Neck CancerPublished: December 17th 2018 | Updated: November 11th 2020
Advertisement
Advertisement
Trending on CancerNetwork
1
Nivolumab/Chemo Yields Long-Term Survival in Advanced Gastric Cancers
2
FDA Grants Fast Track Designation to ART6043/Olaparib in BRCA-Mutated, HER2– Breast Cancer
3
FDA Grants Traditional Approval to Encorafenib in BRAF-Mutated CRC
4
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma
5